What if the world's most widely used medicines could work better?
CV6 Therapeutics is a clinical-stage Genomic Uracil Stress Response (GUSR) platform company developing specific, first-in-class medicines for cancer and inflammatory diseases.
Lead program CV6-168 is currently in Phase 1a clinical development.
Amplifying Cornerstone Cancer Therapies
Thymidylate synthase (TS) inhibitors such as 5-fluorouracil (5-FU) anchor cancer care. Methotrexate anchors rheumatoid arthritis care. Both disrupt nucleotide metabolism, and CV6 medicines are designed to exploit the stress they create.
In cancer, CV6-168 blocks dUTPase to drive uracil into tumor DNA, inducing lethal genomic stress and, in preclinical studies, innate immune signaling. It is being evaluated in an ongoing Phase 1a trial in combination with infusional 5-FU, with no dose-limiting toxicities observed to date.
In rheumatoid arthritis, CV6-1271 applies the same biology alongside methotrexate and is in preclinical development.
Therapies such as 5-FU, capecitabine and pemetrexed are used across first-line, second-line and maintenance treatment in colorectal, breast, gastric, pancreatic, lung, and head and neck cancers.
Methotrexate is the first-line standard of care in rheumatoid arthritis, yet around half of patients respond inadequately.
Each year, approximately 4.8 million newly diagnosed cancer patients receive a TS-directed therapy at some point during their treatment.
Global Cancer Incidence is Rising
Global cancer incidence is projected to approach 30 million cases annually by 2040, representing an increase of approximately 47 percent from 2020 levels, based on GLOBOCAN estimates.
Latest News
View all
Op-Ed: Science Is Not a Medicine. Why Northern Ireland was the right place to build CV6 Therapeutics
We looked for a place where the science would have the strongest opportunity to become a medicine. More than a decade later, as we are advancing through our Phase 1a trial, I remain convinced that we made the right choice.
CV6 Therapeutics Appoints Dr. Chris Takimoto to Board of Directors
CV6 Therapeutics today announced the appointment of veteran oncology drug developer Dr. Chris Takimoto to its Board of Directors as the company advances its lead program, CV6-168, through Phase 1a clinical development.
CV6 Therapeutics Contributes to Discussions on the Future of Oncology Innovation Across Ireland
Dr. Robert D. Ladner, CEO and Founder of CV6 Therapeutics, was invited to join leading voices from industry, healthcare, academia, and government at two major oncology innovation events in Dublin to discuss opportunities to accelerate cancer research, clinical development, and...